Ryota Shibaki

机构：Wakayama Medical University, RIKEN Center for Advanced Intelligence Project, Tokyo National Hospital, National Cancer Research Institute · ORCID：0009-0002-6094-4858

发表论文 70 篇 · 总被引 803 次 · h-index 15

代表论文

• Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT) (2021 · European Journal of Cancer · 被引 92)
• Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (2022 · CHEST Journal · 被引 46)
• Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients (2022 · Clinical Lung Cancer · 被引 20)
• Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer (2024 · Journal for ImmunoTherapy of Cancer · 被引 19)
• Impact of pre‐existing interstitial lung abnormal shadow on lung injury development and severity in patients of non‐small cell lung cancer treated with osimertinib (2022 · Cancer Medicine · 被引 15)
• Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP) (2023 · Lung Cancer · 被引 13)